Walleye Trading
CLDX icon

Walleye Trading’s Celldex Therapeutics CLDX Stock Holding History

Walleye Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,079
Closed -$558K – 4825
2023
Q4 		$558K Buy
14,079
+5,749
+69% +$169K ﹤0.01% 2984
2023
Q3 		$229K Sell
8,330
-208
-2% -$6.52K ﹤0.01% 3514
2023
Q2 		$290K Buy
+8,538
New +$288K ﹤0.01% 3180
2023
Q1 		– Sell
-2,153
Closed -$96K – 4892
2022
Q4 		$96K Sell
2,153
-14,590
-87% -$521K ﹤0.01% 3997
2022
Q3 		$471K Buy
16,743
+3,832
+30% +$117K ﹤0.01% 2965
2022
Q2 		$348K Buy
12,911
+5,224
+68% +$152K ﹤0.01% 3274
2022
Q1 		$262K Buy
+7,687
New +$246K ﹤0.01% 3556
2021
Q4 		– Sell
-3,518
Closed -$190K – 5401
2021
Q3 		$190K Buy
+3,518
New +$165K ﹤0.01% 3905
2020
Q3 		– Sell
-5,714
Closed -$74K – 4162
2020
Q2 		$74K Buy
+5,714
New +$25.3K ﹤0.01% 3656
2018
Q4 		– Sell
-3
Closed – – 4705
2018
Q3 		$0 Buy
+3
New +$21 ﹤0.01% 5300
2017
Q3 		– Sell
-3
Closed – – 4150
2017
Q2 		$0 Buy
+3
New +$133 ﹤0.01% 4534
2016
Q1 		– Sell
-5
Closed -$1K – 5364
2015
Q4 		$1K Buy
+5
New +$1.09K ﹤0.01% 5138

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Walleye Trading's CLDX Position: Q1 2024 in Review

Walleye Trading sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 14,079 shares — an estimated $558K sold.

Walleye Trading first reported a position in CLDX in Q4 2015 and held it in 12 quarters. The position peaked at $558K in Q4 2023. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • Walleye Trading reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Walleye Trading sold 14,079 Celldex Therapeutics shares in Q1 2024, an estimated $558K.
  • Walleye Trading first reported a position in Celldex Therapeutics in Q4 2015 and held it in 12 quarters.
  • Walleye Trading's Celldex Therapeutics position peaked at $558K in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.